ZIOPHARM Oncology, Inc. News
Why 2018 will be better for biotech deals than 2017
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI
Here's what you need to know now for Monday, Jan. 22.
Immunotherapy stocks power higher on Celgene-Juno deal
Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.
Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Judgment Day; Good, Bad and Ugly: Doug Kass' Views
Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.
Biotechs Among 5 Stocks Setting Up for Major Breakouts
Here's how to rake in the profits off some potential big breakouts.
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.
Dr. Doom Sees Plenty of Gloom: Roubini's Bearish Musings
He predicts a global economic and financial crisis, sparked by a debt bubble and accompanied by stagflation.